The ryanodine receptor 1 is encoded by the RYR1 gene on chromosome 19q13.1. The gene comprises 159 000 base pairs with 106 exons. The RYR1-cDNA has a length of 15 117 kb and encodes a protein monomer of 5038 amino acids. 5 The RYR1 is expressed mainly in striated muscle, but there is also a significant level of RYR1 expression in peripheral B-lymphocytes. 6 -8 The exact function of RYR1 in B-lymphocytes is not fully understood.
At present, there are only preliminary data on the genetic basis of MHS in Sweden, 9 and systematic mutation screening has not been performed. The large size of the RYR1 and the distribution of published mutations do not lend themselves to a streamlined diagnostic rationale. With the exception of Switzerland, 10 no founder mutations of significant prevalence have been reported from other populations.
Methods
With Regional Ethics Committee approval, 14 unrelated Swedish MH probands and one Swedish CCD patient, living in Sweden, were contacted by telephone and informed of the study. All MH probands had suffered serious MH clinical reactions and thereafter been tested MHS by IVCT. The CCD patient had been IVC tested as a part of the diagnostic investigations and was also found MHS. All IVCTs were carried out at the National MH Laboratory of Lund University Hospital in southern Sweden. The contractions at the threshold concentrations of caffeine 2.0 mmol litre 21 and halothane 0.44 mmol litre 21 were measured in vitro according to the EMHG protocol.
For each MH proband, the Larach index was also estimated. The Larach index ranks the qualitative likelihood, from 1, almost never, to 6, almost certain, that an adverse anaesthetic event represents MH. This clinical grading scale requires the anaesthesiologist to judge whether specific clinical signs are appropriate for the patient's medical condition, anaesthetic technique, or surgical procedure.
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PAXgene (Qiagen, Hilden, Germany) and standard EDTA test tubes were provided to patients together with a detailed information sheet on blood sampling. All patients had two peripheral venous blood samples drawn at their primary care centres, the first in a PAXgene test tube and the second in an EDTA test tube. The blood samples were immediately sent to the genetic laboratory in Würzburg, Germany, by ordinary mail, a distance up to 2000 km and a transportation time up to 3 days.
Upon arrival in the laboratory, test tubes were stored frozen at 2808C until total RNA was extracted from the PAX tube according to the manufacturer's instructions and genomic DNA of leucocytes from the EDTA tube according to standard protocols. First-strand cDNA was synthesized from 1 mg of total RNA in a final volume of 20 ml using SuperScript TM II (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Owing to the size and nucleotide composition of the RYR1-mRNA, firststrand cDNA was synthesized using three mixes of specific primers as described previously. 12 The resulting first strands were then amplified in 500 -700 bp overlapping fragments using a second set of primers, which are available from the authors on request. Sequencing was performed by BigDye 1.1 on an ABI 3130 XL.
All cDNA sequence variants leading to a change in amino acids were confirmed on genomic DNA from the same patient. A panel of 150 German and 100 Swedish DNA samples from clinically healthy subjects was used to assess the prevalence of the candidate mutations in the normal population. The MH status of these subjects was not known.
Exon 70 was found to be deleted in all cDNA samples and was therefore sequenced from genomic DNA. Likewise, exon 86 was missing in the cDNA of one MH proband and was sequenced from genomic DNA of the particular patient.
In addition, all 15 patients were screened by sequencing for the only known MH causing mutation outside RYR1, the p.Arg1086His mutation in the alpha-1 subunit gene of the dihydropyridine receptor, DHPR (CACNA1S; OMIM *114208), on chromosome 1q32. 13 For segregation studies, the IVC-tested family members of the probands were identified from records. Genomic DNA was extracted from left over muscle tissue biopsied at the time of the IVCTs and stored at 2808C. The age of the muscle pieces varied from ,1 to .10 yr. The probands' sequence variants were either confirmed or excluded by direct sequencing of the relevant exon of the RYR1.
Results
Descriptive, IVCT, Larach index, and RYR1 sequence variant data are presented in Table 1 .
Eight of 15 patients (53%) in our cohort, consisting of 14 MH probands and one CCD patient, showed either a known mutation or a novel sequence variant. All sequence variants could be verified on genomic DNA and were absent from 300 German and 200 Swedish control chromosomes with two exceptions (see below).
Two MH probands had known MH causing mutations (www.emhg.org): p.Gly248Arg and p.Arg614Leu. In addition to the mutation p.Gly248Arg, the former proband showed two unreported amino acid substitutions: p.Arg1583Cys and p.Glu5034Val.
One MH proband had the mutation p.Val4849Ile which has been previously associated with MHS in the heterozygous state 14 and with congenital multi-minicore disease when homozygous. 15 However, this variant was previously found once in a healthy control.
14 Therefore, its functional impact remains to be elucidated.
In four additional MH probands, novel amino acid substitutions were found: p.Glu1058Lys, p.Arg1679His, p.His382Asn and p.Lys1393Arg. The substitution p.Arg1679His was found in one German control sample and the substitution p.Lys1393Arg was found in one Swedish control sample.
The CCD patient had the sequence variant p.Arg2508Gly. This variant has been found once before in a CCD patient from Japan. 16 Our segregation data were limited by the number of family members IVC tested. The available segregation data are shown in Figure 1 .
The variant p.Arg1679His (Fig. 1A ) was carried by two MHS individuals and by two MHE individuals in the pedigree, but absent from two MHN individuals. However, a third MHN individual (1374, child of the MHE individual 1327) also carried the sequence variant.
The variant p.His382Asn (Fig. 1B ) perfectly cosegregated with MHS status in the small nuclear family available.
Seven IVC-tested relatives of Patient 8 carrying the variants p.Arg1583Cys and p.Glu5034Val together with the known mutation p.Gly248Arg were available for a segregation study. The variant p.Arg1583Cys and the mutation p.Gly248Arg are co-inherited in cis on a familiar haplotype (black bars in Fig. 1C ). In contrast, the variant p.Glu5034Val was introduced on a different haplotype (hatched bars) by the unrelated MHN spouse (1045) and segregated in two MHS (949, 984) and two MHN individuals (985, 1732). It can therefore be excluded as being causative for the MHS disposition in this family. No conclusion can be drawn from the observed segregation for the variant p.Arg1583Cys.
Segregation analysis for the variants p.Glu1058Lys, p.Arg2508Gly, and p.Lys1393Arg was not possible because of the limited IVC testing in these families.
Seven patients of 15 (47%) in our cohort did not show any known mutation or candidate mutation in the entire RYR1-cDNA sequence synthesized from total RNA isolated from B-lymphocytes. None of the 15 patients showed the MH causative mutation p.Arg1086His in the alpha-1 subunit of the CACNA1S gene.
Discussion
The aim of the present study was a systematic screening of the total coding region of the RYR1 gene in a cohort of 15 Mutation screening of the RYR1-cDNA from peripheral B-lymphocytes MHS index patients from Sweden. For logistic reasons, we designed a simple and practical protocol for the collection of blood samples drawn at the patients' local primary care centres. The protocol included two venous peripheral blood samples of 5 ml each, the first in a PAXgene test tube for mRNA extraction and the second in an EDTA test tube for genomic DNA preparation. Since PAXgene test tubes are not normally available at primary care centres, they were sent to the patients before sampling.
With the RNA stabilizer used in the PAXgene tubes, we managed to extract sufficient RYR1-mRNA from all samples after 2 -3 days of transportation at ambient temperature over a distance up to 2000 km. RYR1-cDNA was synthesized from the RYR1-mRNA fraction of B-lymphocytes for direct sequencing, and sequence variants were confirmed on genomic DNA isolated from leucocytes.
In a previous study of 27 Swedish MHS probands, only exons 17, 39, 40, 45, and 46 were screened on genomic DNA. These exons harbour 14 published MH-related mutations (www.emhg.org) which together cover about 45% of all cases in a German MHS-population (C.R.M., unpublished data). In contrast, only five mutations (19%) were identified among the 27 Swedish probands. 9 This suggested that the mutation spectra differ between the Nordic and the Central European MHS populations.
Upon screening of the entire coding region of the RYR1 from cDNA derived from B-lymphocytes, 10 amino acid substitutions were identified in eight of 15 patients raising the detection rate to 53%. Patient 5 ( p.Val4849Ile), Patient 8 ( p.Gly248Arg), and Patient 14 ( p.Arg614Leu) carried mutations which have been reported before (www.emhg.org). The latter two have been extensively tested by segregation, functional, or both studies 17 -19 and are considered causative of MH by the EMHG criteria. 14 19 The p.Val4849Ile substitution is more puzzling: as a homozygous genotype, it has been reported to cause a severe congenital form of multi-minicore myopathy. 15 However, Monnier and colleagues 14 found this as a heterozygous genotype in MHS probands but also once among 100 healthy control subjects. Pharmacological activation of immortalized B-lymphocytes carrying this mutation homozygously showed a small but significant effect on resting calcium concentration but did not alter the amount of calcium released after RYR1 activation. 20 The mutation carrier in our study does not have any clinical signs of myopathy or a diagnosis of CCD, but she suffered a severe MH reaction during anaesthesia with inhalation anaesthetics. Thus, the functional relevance of this amino acid substitution remains to be elucidated. The only CCD patient in our study; Patient 15 carried the substitution p.Arg2508Gly which has been found once before in a Japanese CCD patient, but its significance as a causative mutation has not been elucidated. The evidence for disease causality of the variants presented in this study must be considered incomplete and circumstantial.
(i) All substitutions affect amino acids which are highly or perfectly conserved in the RYR proteins from several vertebrates (Fig. 2) . Conservation of protein domains over long evolutionary distances is generally thought to indicate functional relevance. Substitution of an amino acid within such a domain is, therefore, regarded to compromise the function of the protein with the potential sequela of disease. (ii) All variants were absent from 300 German and 200
Swedish control chromosomes with two exceptions: the substitution p.Arg1679His was found in one German control and the substitution p.Lys1393Arg in one Swedish control. Since the MH status of the control subjects was not known, these individuals might have an as yet undiagnosed MH predisposition. Alternatively, the substitutions of Arg1679 by histidine and Lys1393 by arginine may be 'neutral' polymorphisms, although they both occurred in highly conserved domains (Fig. 2) . (iii) The available segregation data are too limited to formally prove causality for any of the novel sequence variants found. However, co-segregation could be observed in a small nuclear family for p.His382Asn (Fig. 1B) and for the two linked variants p.Gly248Arg and p.Arg1583Cys (Fig. 1C) . In this family, the segregation study allowed an exclusion of the third variant p.Glu5034Val as the causative mutation for MHS. In the third pedigree studied, the variant p.Arg1679His occurred in all MHS and MHE family members but also in one MHN individual (Fig. 1A) . Interestingly, the substitution was also found in one of 150 German, but not in 100 Swedish controls. Thus, p.Arg1679His could also be a neutral variant.
The discordance between IVCT results and mutation data has been assessed in a large segregation study of MH causative mutations in 196 European pedigrees and was found to be 10%. 21 Discordance was observed in both directions: MHS individuals who did not carry their family's mutation and MHN individuals who did. It is not known, however, whether these data reflect the false-positive and falsenegative error rates of IVCT or have other reasons.
Few studies have screened the total RYR1 coding region: in Japan, a mutation was found in 57%, 22 in a North American study in 70%, 19 in a British cohort in 70%, 5 and in an Italian cohort in 86% 23 of the patients screened. In comparison, the detection rate of 53% in our study must be considered low. from the same patient. This demonstrates that the reverse transcriptase used (see Methods) worked with high fidelity.
With cDNA synthesis and subsequent PCR, there is always the concern of selective amplification or allele drop-out due to large heterozygous deletions. The large number of single nucleotide polymorphic variants, which were detected (see additional material in the electronic version), can be considered as a good though not perfect monitor for allele loss. Furthermore, it has been shown that allele silencing of RYR1 by epigenetic or other mechanisms leads to severe congenital myopathies. 25 26 Thus, quantitative defects of RYR1 expression are not compatible with normal muscle function. It is therefore highly unlikely that hitherto undetected large heterozygous deletions contribute to the genetic aetiology of MH.
According to our sequencing results, in about half of the patients included in our cohort, no candidate mutation was found in the RYR1. This raises the question whether other genes contribute to the aetiology of MH in Swedish probands. The only MH-related mutation in the alpha-1 subunit of the CACNA1S gene, p.Arg1086His, has been ruled out, but the remainder of this large gene has not been analysed.
As a conclusion, the present study underlines the heterogeneity of the genetic background of MH. With the present evidence, the novel variants observed should be considered candidate mutations for MH and CCD, respectively. Experiments are underway to study the impact of the identified amino acid substitution on RYR1 function in order to draw final conclusions on their relevance for MH disposition.
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